Here are a few brief analogies for Nuvalent:

• It's like an early-stage Blueprint Medicines or Loxo Oncology (now part of Eli Lilly), developing next-generation precision cancer drugs to overcome resistance.
• Think of it as a specialized, clinical-stage Genentech (now part of Roche), focused on creating highly targeted therapies for difficult-to-treat cancers, including those that spread to the brain.

Major Products of Nuvalent (NUVL):

• NVL-520: A brain-penetrant ROS1-selective inhibitor in Phase I development for treating cancer patients with ROS1 fusions, including those with drug-resistant mutations.
• NVL-655: A brain-penetrant ALK-selective inhibitor in Phase I/II clinical trial designed to overcome treatment resistance and central nervous system challenges in ALK-driven cancers.

Nuvalent, Inc. (NUVL) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its lead product candidates, NVL-520 and NVL-655, are currently in Phase I and Phase I/II clinical trials, respectively.

As a clinical-stage company, Nuvalent's products are not yet approved for commercial sale and therefore it does not currently have major customers in the traditional sense who purchase its products. Its primary activities are research, development, and clinical trials aimed at achieving regulatory approval.

null

James Porter, Chief Executive Officer

James Porter, Ph.D., joined Nuvalent during its creation in 2018 and became Chief Executive Officer and a Director in January 2020. He has two decades of oncology drug development experience. Prior to Nuvalent, he spent 15 years at Infinity Pharmaceuticals, where he was one of the initial scientists and gained extensive company-building experience, leading teams in medicinal chemistry, pharmaceutical development, alliance management, program management, and product development, rising to Vice President of Product Development. He led the duvelisib Product Development team from development candidate nomination through NDA submission, which led to the FDA approval of COPIKTRA®. He also led the transition, Product Development team, and NDA submission at Verastem Oncology after its acquisition of the duvelisib program during Phase 3 clinical development.

Alexandra Balcom, Chief Financial Officer

Alexandra Balcom, MBA, CPA, joined Nuvalent as Chief Financial Officer in January 2021, bringing over 15 years of strategic, financial, and operational experience in the biotechnology industry. Before Nuvalent, she was Vice President of Finance at SQZ Biotechnologies, where she helped raise over $200 million in private and public equity financing, including the 2020 initial public offering. Prior to SQZ, she served as Corporate Controller at Agios Pharmaceuticals, where she built finance and accounting teams and played a key role in raising more than $700 million in equity financing, including the 2013 initial public offering. Earlier in her career, she held positions at Molecular Insight Pharmaceuticals, a publicly-traded oncology company acquired in 2013, and Coley Pharmaceuticals, a publicly-traded company acquired by Pfizer in 2007.

Christopher D. Turner, Chief Medical Officer

Christopher D. Turner, M.D., joined Nuvalent in March 2021 as Chief Medical Officer and has over 20 years of clinical and pharmaceutical experience in oncology drug development. Before Nuvalent, he was Vice President of Clinical Development at Blueprint Medicines, where he oversaw the development and approval of GAVRETO™ (pralsetinib) for RET fusion positive non-small cell lung cancer (NSCLC) and RET altered thyroid cancer. He also led the development of novel ADC and immune-oncology compounds at Celldex Therapeutics, and the clinical development of ICLUSIG® (ponatinib) and ALUNBRIG® (brigatinib) at Ariad Pharmaceuticals, both of which have since been approved for cancer patients. Previously, Dr. Turner was Director of the Pediatric Neuro-Oncology Outcomes Clinic at Dana-Farber Cancer Institute/Children's Hospital Boston.

Henry Pelish, Chief Scientific Officer

Henry Pelish, Ph.D., was promoted to Chief Scientific Officer in July 2024. He contributed to the creation of Nuvalent and joined the company as Biology lead in 2018, overseeing the discovery and early-stage development of NVL-520, NVL-655, and NVL-330, and ongoing research efforts. Dr. Pelish has over 15 years of experience in cancer biology, chemical biology, and organic synthesis. Prior to Nuvalent, he was a group leader in the laboratory of Professor Matthew Shair at Harvard University, where he led a team that discovered a new target, mechanism of action, and therapeutic opportunity for acute myeloid leukemia, which culminated in a licensing deal and research agreement between Harvard and Merck.

Deborah Ann Miller, Chief Legal Officer & Secretary

Deborah Ann Miller, J.D., Ph.D., serves as Nuvalent's Chief Legal Officer and Secretary, having been appointed in September 2021. Prior to Nuvalent, Dr. Miller was Chief IP Counsel & Deputy General Counsel at Sumitomo Pharma America, Inc. from 2017 to 2020. She also served as Chief Patent Counsel & Deputy General Counsel at Infinity Pharmaceuticals, Inc. from 2010 to 2017. Earlier in her career, Dr. Miller was IP corporate counsel at Sepracor Inc. (currently Sunovion Pharmaceuticals Inc.), and an associate at Nutter McClennen & Fish LLP. She holds a J.D. from Suffolk University Law School, a Ph.D. in biological chemistry and molecular pharmacology from Harvard University, an M.S. in medical sciences from Harvard Medical School, and a B.S. in chemistry from Swarthmore College.

Key Risks for Nuvalent (NUVL)

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Nuvalent's primary business success hinges on its drug candidates, NVL-520 and NVL-655, successfully completing rigorous clinical trials (currently in Phase I and Phase I/II, respectively) and ultimately obtaining regulatory approvals. There is a high risk that these product candidates may fail to demonstrate efficacy or safety, encounter unexpected adverse events, or not receive necessary regulatory clearances, which would significantly jeopardize the company's future prospects and ability to generate revenue.

2. Intense Competition: Nuvalent operates in the highly competitive oncology market. Its drug candidates, such as NVL-655, are designed to address limitations of existing therapies (e.g., first-, second-, and third-generation ALK inhibitors), indicating an already established and active competitive landscape. Other biopharmaceutical companies may develop similar, more effective, or more cost-efficient therapies, which could limit Nuvalent's market share and profitability even if its products successfully gain approval.

3. Intellectual Property Protection: The value of Nuvalent's pipeline and future revenue streams are heavily dependent on its ability to obtain, maintain, and enforce robust patent protection for its drug candidates and related technologies. Failure to secure adequate intellectual property rights, challenges to existing patents from competitors, or the inability to prevent unauthorized use of its discoveries could significantly diminish the commercial value of its product candidates and negatively impact the business.

null

Nuvalent's main product candidates, NVL-520 and NVL-655, target distinct patient populations within non-small cell lung cancer (NSCLC).

NVL-520 (ROS1-positive NSCLC)

The addressable market for ROS1-positive NSCLC, the target indication for NVL-520, has varying estimations depending on the scope and year. In 2024, the total market size in the 7MM (United States, EU4, United Kingdom, and Japan) for ROS1 NSCLC by line of therapy was estimated to be nearly USD 300 million, with the United States holding the largest share of this market. Globally, the market for targeted drug ROS1 inhibitors for NSCLC was valued at approximately $1.2 billion in 2023 and is projected to reach $3.1 billion by 2032, with North America currently dominating this market. Another estimate from April 2025 suggests the entire market size for ROS1-positive NSCLC falls between $500 million and $2.25 billion.

NVL-655 (ALK-positive NSCLC)

For ALK-positive NSCLC, the target for NVL-655, the addressable market is significantly larger. In 2023, the ALK Metastatic NSCLC market in the U.S. was estimated to be nearly USD 915 million. The total ALK Metastatic NSCLC market size across the 7MM was approximately USD 1.53 billion in 2023. More recent projections for the ALK NSCLC market size in the 7MM were around USD 2 billion in 2024, with an anticipated increase through 2034. Specifically for the U.S., the ALK NSCLC market size exceeded USD 1.2 billion in 2024. Globally, the ALK-positive lung cancer treatment market is expected to grow from USD 1.69 billion in 2025 to USD 10.60 billion by 2032. Another report estimates the global market size at USD 4.7 billion in 2025, projected to reach USD 9.8 billion by 2032, with North America expected to be the dominant region.

Nuvalent (NUVL) is poised for potential future revenue growth over the next 2-3 years, primarily driven by the advancement and anticipated commercialization of its lead product candidates. As a clinical-stage biopharmaceutical company, its revenue trajectory is closely tied to regulatory milestones and market expansion of its precision oncology therapies. The key expected drivers of future revenue growth for Nuvalent include: * U.S. Commercial Launch of Zidesamtinib (NVL-520) in TKI Pre-treated ROS1-Positive NSCLC: Nuvalent anticipates the potential U.S. commercial launch of zidesamtinib (NVL-520) in 2026 for patients with TKI pre-treated advanced ROS1-positive non-small cell lung cancer (NSCLC). The FDA accepted the New Drug Application (NDA) for zidesamtinib, assigning a PDUFA target action date of September 18, 2026, and commercial preparations are actively underway. * Potential Label Expansion for Zidesamtinib (NVL-520) in TKI-Naïve ROS1-Positive NSCLC: Further expanding the market opportunity, Nuvalent plans to submit data to the FDA in the second half of 2026 to support a potential label expansion for zidesamtinib (NVL-520) to include TKI-naïve patients with advanced ROS1-positive NSCLC. * Regulatory Submission and Potential Approval of Neladalkib (NVL-655) in TKI Pre-treated ALK-Positive NSCLC: Nuvalent intends to submit an NDA for neladalkib (NVL-655) in the first half of 2026 for TKI pre-treated patients with advanced ALK-positive NSCLC. This follows anticipated pivotal data from the ALKOVE-1 trial by year-end 2025, which would introduce a second potential commercial product to the company's portfolio. * Advancement of Neladalkib (NVL-655) into First-Line ALK-Positive NSCLC: Beyond the pre-treated setting, Nuvalent is progressing with the Phase 3 ALKAZAR trial, which is evaluating neladalkib (NVL-655) against Roche's Alecensa in first-line ALK-positive NSCLC. While the trial completion is slated for 2029, progress in this pivotal study, which was expected to start in the first half of 2025, will be a significant indicator of future revenue potential.

Share Issuance

• Nuvalent raised $471.8 million in November 2025 through the sale of 4,950,496 shares of Class A common stock.
• The company conducted public offerings in 2024 and 2023, raising $540.0 million and $323.5 million, respectively.
• Nuvalent's additional paid-in capital increased to $2.218 billion in 2025, marking a 37.2% increase from 2024. This also followed a 63.85% increase in 2024 to $1.617 billion from 2023, and a 58.26% increase in 2023 to $0.987 billion from 2022.

Capital Expenditures

• Nuvalent reported $0.00 in capital expenditures for each year from 2020 through 2025.
• The company's primary capital allocation focus is on research and development (R&D) expenses, which amounted to $307.0 million for the year ended December 31, 2025.